Deal sells notes with warrants for 1,349,998 shares to Redmile Capital
By Devika Patel
Knoxville, Tenn., Oct. 1 – Amicus Therapeutics, Inc. raised $50 million in a private placement of 4.1% unsecured promissory notes with Redmile Capital Fund, LP on Oct. 1, according to an 8-K filed Thursday with the Securities and Exchange Commission.
Redmile also received warrants for 1,349,998 shares. Each warrant is exercisable for five years.
Amicus is a Cranbury, N.J., biopharmaceutical company.
| Issuer: | Amicus Therapeutics, Inc.
|
| Issue: | Unsecured promissory notes
|
| Amount: | $50 million
|
| Coupon: | 4.1%
|
| Warrants: | For 1,349,998 shares
|
| Warrant expiration: | Five years
|
| Investor: | Redmile Capital Fund, LP
|
| Settlement date: | Oct. 1
|
| Stock symbol: | Nasdaq: FOLD
|
| Stock price: | $13.99 at close Sept. 30
|
| Market capitalization: | $1.63 billion
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
